Loading...

Brilliant Violet 421™ anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1.2F3_BV421_071911
PMA+ionomycin-stimulated (6 hours) C57BL/6 mouse splenocytes were stained with CD69 (clone H1.2F3) Brilliant Violet 421™ (filled histogram) or Armenian hamster IgG Brilliant Violet 421™ isotype control (open histogram).
  • H1.2F3_BV421_071911
    PMA+ionomycin-stimulated (6 hours) C57BL/6 mouse splenocytes were stained with CD69 (clone H1.2F3) Brilliant Violet 421™ (filled histogram) or Armenian hamster IgG Brilliant Violet 421™ isotype control (open histogram).
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
104527 125 µL 193 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104545 50 µg 242 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104528 500 µL 413 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  2. Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed
  3. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  4. Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed
  5. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  6. Barberio AE, et al. 2023. Bioeng Transl Med. 8:e10453. PubMed
  7. Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed
  8. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  9. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  10. Barberio AE, et al. 2020. ACS Nano. 14:11238. PubMed
  11. Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941. PubMed
  12. Yu S, et al. 2016. Mol Ther. 10.1038/mt.2016.175. PubMed
  13. Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed
  14. Kim S, et al. 2021. Elife. 10:. PubMed
  15. Chandana M, et al. 2022. Nat Commun. 13:4028. PubMed
  16. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  17. Jin C, et al. 2019. Cell. 176:998. PubMed
  18. Beura LK, et al. 2018. Immunity. 48:327. PubMed
  19. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  20. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  21. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  22. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  23. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  24. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
RRID
AB_10900250 (BioLegend Cat. No. 104527)
AB_10900250 (BioLegend Cat. No. 104545)
AB_10900250 (BioLegend Cat. No. 104528)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD69
Specificity Alt (DOES NOT SHOW ON TDS):
CD69
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD69 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 3    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account